Jiang Yan, Zhang Qichang, Wang Haoyu, Tang Dabei, Zhang Yan, Yu Li
Department of Traditional Chinese Medicine, The First Hospital of Qiqihar City, Qiqihar City 161000, China.
Department of Basic Science of Traditional Chinese Medicine, Heilongjiang University of Chinese Medicine, Harbin City 150040, China.
Iran J Public Health. 2020 May;49(5):886-895.
To explore IFN-γ (interferon-γ) and IL-4 (interleukin-4) expressions before and after the treatment of LN (lupus nephritis) and their values for efficacy prediction and evaluation.
Altogether 107 patients with LN treated in the First Hospital of Qiqihaer City, Qiqihar, China from March 2017 to September 2018 were enrolled. Sixty-two patients were treated with cyclophosphamide and prednisolone (control group), while another 45 patients were treated with Qing Shen Fang based on the control group (observation group). Their clinical efficacy and changes in immune indices after treatment were observed.
Compared with those in the control group, clinical efficacy, IFN-γ, IL-4, hemoglobin, complements C3 and C4, ESR (erythrocyte sedimentation rate), serum IgG, SLEDAI (Systemic Lupus Erythematosus Disease Activity Index) score, and TCMSSS (Traditional Chinese Medicine Syndrome Score Scale) score were significantly improved after treatment in the study group. Based on the observation, IFN-γ and IL-4 could be used as potential indicators for evaluating clinical efficacy.
The combination of cyclophosphamide, prednisolone, and Qing Shen Fang improves conditions of patients with LN and significantly reduces their IFN-γ and IL-4 levels in serum. IFN-γ and IL-4 can be used as potential indicators for the efficacy prediction and evaluation of the disease.
探讨狼疮性肾炎(LN)治疗前后干扰素-γ(IFN-γ)和白细胞介素-4(IL-4)的表达情况及其在疗效预测和评估中的价值。
选取2017年3月至2018年9月在齐齐哈尔市第一医院接受治疗的107例LN患者。62例患者接受环磷酰胺和泼尼松龙治疗(对照组),另外45例患者在对照组基础上加用清肾方治疗(观察组)。观察两组患者的临床疗效及治疗后免疫指标的变化。
与对照组相比,治疗后研究组的临床疗效、IFN-γ、IL-4、血红蛋白、补体C3和C4、红细胞沉降率(ESR)、血清IgG、系统性红斑狼疮疾病活动指数(SLEDAI)评分及中医证候积分量表(TCMSSS)评分均显著改善。根据观察结果,IFN-γ和IL-4可作为评估临床疗效的潜在指标。
环磷酰胺、泼尼松龙与清肾方联合应用可改善LN患者的病情,并显著降低其血清IFN-γ和IL-4水平。IFN-γ和IL-4可作为该疾病疗效预测和评估的潜在指标。